Active Filter(s):
Details:
NB-110 comprises of a synthetic cannabinoid Nabilone in the absence of any preservative and its formulation mimics a human tear to drive efficacious delivery through the cornea to the retina and optical nerves in the back of eye.
Lead Product(s): Nabilone
Therapeutic Area: Ophthalmology Product Name: NB-110
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Ault Global Holdings
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition June 28, 2021